Vaxcyte (NASDAQ:PCVX) CEO Grant Pickering Sells 22,461 Shares

Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering sold 22,461 shares of the stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $52.50, for a total transaction of $1,179,202.50. Following the transaction, the chief executive officer owned 474,703 shares of the company’s stock, valued at $24,921,907.50. The trade was a 4.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Grant Pickering also recently made the following trade(s):

• On Thursday, June 18th, Grant Pickering sold 2,000 shares of Vaxcyte stock. The shares were sold at an average price of $52.50, for a total transaction of $105,000.00.

Vaxcyte Price Performance

NASDAQ:PCVX traded up $0.77 on Thursday, hitting $51.44. 2,837,023 shares of the company’s stock were exchanged, compared to its average volume of 1,270,669. The firm has a 50-day moving average price of $53.56 and a 200-day moving average price of $52.70. Vaxcyte, Inc. has a 52 week low of $29.08 and a 52 week high of $65.00. The company has a market cap of $7.43 billion, a P/E ratio of -7.48 and a beta of 1.24.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same quarter in the prior year, the company posted ($1.04) earnings per share. On average, research analysts expect that Vaxcyte, Inc. will post -7.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Wall Street Zen cut Vaxcyte from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 28th. Jefferies Financial Group reissued a “buy” rating on shares of Vaxcyte in a research note on Tuesday, March 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research note on Wednesday, April 8th. Finally, BTIG Research boosted their price objective on shares of Vaxcyte from $85.00 to $89.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Vaxcyte has a consensus rating of “Moderate Buy” and a consensus target price of $86.00.

Institutional Investors Weigh In On Vaxcyte

Large investors have recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC boosted its position in Vaxcyte by 156.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock worth $27,000 after purchasing an additional 364 shares during the period. Caitong International Asset Management Co. Ltd raised its position in shares of Vaxcyte by 1,463.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock valued at $30,000 after purchasing an additional 600 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Vaxcyte by 33.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock valued at $34,000 after purchasing an additional 184 shares during the period. Capital Advisors Ltd. LLC acquired a new stake in shares of Vaxcyte during the 1st quarter worth about $58,000. Finally, Allworth Financial LP lifted its stake in shares of Vaxcyte by 148.9% during the 3rd quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock worth $44,000 after buying an additional 731 shares during the last quarter. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.